Theriva Biologics, Inc. (TOVX) — SEC Filings
Theriva Biologics, Inc. (TOVX) — 50 SEC filings. Latest: 8-K (Dec 29, 2025). Includes 36 8-K, 5 10-Q, 2 DEF 14A.
View Theriva Biologics, Inc. on SEC EDGAR
Overview
Theriva Biologics, Inc. (TOVX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 15, 2025: On December 15, 2025, Theriva Biologics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 9605 Medical Center Drive, Suite 270, Rockville, Maryland 20850. The company was formerly known as Synthetic Biologics, Inc. and ADEONA PHARMACEUTICALS, IN
Sentiment Summary
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant filing sentiment for Theriva Biologics, Inc. is neutral.
Filing Type Overview
Theriva Biologics, Inc. (TOVX) has filed 36 8-K, 2 DEF 14A, 5 10-Q, 2 S-1/A, 1 10-K, 2 S-1, 2 SC 13G with the SEC between May 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (50)
Risk Profile
Risk Assessment: Of TOVX's 46 recent filings, 1 were flagged as high-risk, 21 as medium-risk, and 24 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | -$10.5M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Steven A. Shallcross
Industry Context
Theriva Biologics operates in the biotechnology sector, which is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this space often rely on private placements and warrant exercises to fund ongoing operations and clinical trials, especially in the early stages of development. The competitive landscape is intense, with numerous companies vying for funding and market share in specific therapeutic areas.
Top Tags
8-K (7) · sec-filing (7) · financials (7) · disclosure (6) · company-update (5) · 8-k (5) · corporate-governance (4) · financial-condition (4) · 10-Q (4) · address-change (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares of common stock | 16,184,560 | Maximum shares to be issued upon exercise of New Warrants, requiring stockholder approval |
| Exercise price per share | $0.54 | Reduced exercise price for Existing Warrants and exercise price for New Warrants |
| Shares of common stock outstanding | 33,739,643 | As of the record date, October 30, 2025 |
| Quorum requirement | 34% | Percentage of outstanding shares required for transaction of business at the Special Meeting |
| September Warrant Shares | 1,345,000 | Shares issued upon exercise of September Warrants |
| May Warrant Shares | 6,747,280 | Shares issued upon exercise of May Warrants |
| New Warrants issuance ratio | 200% | New Warrants issued at 200% of Existing Warrant Shares exercised |
| Beneficial ownership limit | 4.99% | Initial cap for New Warrant exercise, adjustable to 9.99% |
| Meeting frequency obligation | 60 days | Frequency of subsequent meetings if stockholder approval is not obtained |
| Closing Date | October 17, 2025 | Date of the private placement offering and Warrant Inducement consummation |
| Commission File Number | 001-12584 | SEC filing identifier |
| IRS Employer Identification No. | 13-3808303 | Company tax identifier |
| Revenue | $0 | No revenue reported for Q2 2025, indicating a clinical-stage company. |
| Net Loss (Q2 2025) | $10.5M | Increased from $9.8M in Q2 2024, showing widening losses. |
| Net Loss (YTD Q2 2025) | $20.1M | Increased from $19.0M in YTD Q2 2024, reflecting continued operational expenses. |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Theriva Biologics, Inc. (TOVX)?
Theriva Biologics, Inc. has 50 recent SEC filings from May 2024 to Dec 2025, including 36 8-K, 5 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TOVX filings?
Across 50 filings, the sentiment breakdown is: 1 bearish, 48 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Theriva Biologics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Theriva Biologics, Inc. (TOVX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Theriva Biologics, Inc.?
Key financial highlights from Theriva Biologics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TOVX?
The investment thesis for TOVX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Theriva Biologics, Inc.?
Key executives identified across Theriva Biologics, Inc.'s filings include Steven A. Shallcross.
What are the main risk factors for Theriva Biologics, Inc. stock?
Of TOVX's 46 assessed filings, 1 were flagged high-risk, 21 medium-risk, and 24 low-risk.
What are recent predictions and forward guidance from Theriva Biologics, Inc.?
Forward guidance and predictions for Theriva Biologics, Inc. are extracted from SEC filings as they are enriched.